ArticleCureus2025
Severity of Non-Alcoholic Fatty Liver Disease Assessed by FibroScan in Patients With and Without Ischemic Heart Disease: A Cross-Sectional Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease and is closely linked to metabolic risk factors that also predispose to ischemic heart disease (IHD). Evaluating the relationship between NAFLD severity and IHD may improve cardiovascular risk assessment. Objective To compare the severity of NAFLD, assessed by FibroScan, in patients with and without IHD. Methods A cross-sectional study was conducted at Liaquat National Hospital, Karachi (Sept 2023-Feb 2024). Adults with NAFLD confirmed by FibroScan were enrolled (n=300), including 100 IHD patients and 200 non-IHD controls. Anthropometric, biochemical, and FibroScan parameters (Controlled Attenuation Parameter (CAP) and Liver Stiffness Measurement (LSM)) were recorded. Between-group differences were analyzed using t-tests and Chi-square tests, and logistic regression was used to estimate associations, adjusting for age, sex, and BMI. Results Among the 300 patients (mean age 51.4 ± 8.5 years; 62.2% female), obesity (99.1%), diabetes (54.8%), and dyslipidemia (62.7%) were prevalent comorbidities. Mean FibroScan values did not differ significantly between IHD and control groups (7.2±2.05 vs 7.03±2.16 kPa, p=0.507). CAP scores were also comparable (273.3±65.0 vs 282.2±66.6 dB/m, p=0.276). Logistic regression showed mild CAP associated with higher IHD odds (OR 2.21, 95% CI 1.04-4.72, p=0.04), but no consistent associations were observed with fibrosis stage. Conclusions The severity of non-alcoholic fatty liver disease (NAFLD), assessed non-invasively by FibroScan, did not differ significantly between patients with and without ischemic heart disease (IHD). A borderline association between mild hepatic steatosis (CAP) and IHD was observed; however, this finding should be interpreted with caution, as it lacked a dose-response pattern and histologic (biopsy) confirmation. Given the cross-sectional design, the results indicate an association rather than causation, underscoring the need for longitudinal, biopsy-validated studies to better clarify the hepatic-cardiovascular relationship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.